Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pharmacyclics LLC.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Steroid dependent or refractory classic chronic GVHD disease.
No more than 3 previous treatments for cGVHD.
Receiving baseline systemic glucocorticoid therapy (at stable dose) for cGVHD at study entry.
Men and women ≥18 years old.
Karnofsky performance status ≥60.
You may not be if
Known or suspected active acute GVHD.
Current treatment with sirolimus AND either cyclosporine or tacrolimus.
History of treatment with a tyrosine kinase inhibitor (eg, imatinib), purine analogs or other cancer chemotherapy in the 4 weeks prior to starting study drug.
Currently active, clinically significant cardiovascular disease.
Uncontrolled infections not responsive to antibiotics, antiviral medicines, or antifungal medicines or a recent infection requiring systemic treatment that was completed ≤14 days before the first dose of study drug.
Progressive underlying malignant disease including post-transplant lymphoproliferative disease.
History of other malignancy (not including the underlying malignancy that was the indication for transplant)
Concomitant use of warfarin or other Vitamin K antagonists
Known bleeding disorders or hemophilia.
History of stroke or intracranial hemorrhage within 6 months prior to enrollment.
Known history of human immunodeficiency virus (HIV) or active with hepatitis C virus (HCV) or hepatitis B virus (HBV).
Concurrent use of a strong cytochrome P450(CYP) 3A inhibitor.
Clareo Health | Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host Disease
